Alkon Daniel L. 4
4 · Neurotrope, Inc. · Filed Nov 27, 2020
Insider Transaction Report
Form 4
Neurotrope, Inc.NTRP
Alkon Daniel L.
President
Transactions
- Award
Stock Option (right to buy)
2020-11-24+40,000→ 40,000 totalExercise: $0.97Exp: 2030-11-24→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros.